用于治疗艾滋病毒的两种每日一次的固定剂量核苷类逆转录酶抑制剂组合。
Two-once-daily fixed-dose NRTI combinations for HIV.
出版信息
Med Lett Drugs Ther. 2005 Feb 28;47(1203):19-20.
PMID:15767973
Abstract
Abacavir/lamivudine (Epzicom) and emtricitabine/tenofovir (Truvada), two new once-daily fixed-dose NRTI combinations, have been approved for use in antiretroviral regimens to treat HIV infection. Epzicom appears to be as effective as its components taken separately and, in one study, Truvada was at least as effective as zidovudine/lamivudine (Combivir). Use of once-daily fixed-dose combinations means less flexibility in dosing, and some patients with hepatic or renal impairment will not be able to take them.
摘要
阿巴卡韦/拉米夫定（依非韦伦）和恩曲他滨/替诺福韦（特鲁瓦达）是两种新型的每日一次固定剂量核苷类逆转录酶抑制剂组合药物，已被批准用于抗逆转录病毒治疗方案以治疗HIV感染。依非韦伦似乎与其单独使用的成分效果相同，并且在一项研究中，特鲁瓦达至少与齐多夫定/拉米夫定（双汰芝）效果相当。每日一次固定剂量组合药物的使用意味着给药灵活性降低，一些肝肾功能不全的患者将无法使用。
相似文献
1
Two-once-daily fixed-dose NRTI combinations for HIV.用于治疗艾滋病毒的两种每日一次的固定剂量核苷类逆转录酶抑制剂组合。
Med Lett Drugs Ther. 2005 Feb 28;47(1203):19-20.
2
Switching Combivir to Truvada keeps HIV undetectable, improves blood fats, fails to improve limb fat.将双汰芝换成特鲁瓦达可使艾滋病毒检测不到，改善血脂，但不能改善肢体脂肪。
Proj Inf Perspect. 2008 Dec(47):8.
3
Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.阿巴卡韦-拉米夫定每日一次固定剂量联合用药与阿巴卡韦和拉米夫定分成分每日两次给药的短期安全性和耐受性比较：ALOHA研究结果
Pharmacotherapy. 2008 Mar;28(3):314-22. doi: 10.1592/phco.28.3.314.
4
A truvada hypersensitivity reaction simulating abacavir hypersensitivity.一种模拟阿巴卡韦超敏反应的特鲁瓦达超敏反应。
AIDS. 2007 Oct 18;21(16):2252-3. doi: 10.1097/QAD.0b013e3282f08b84.
5
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.替诺福韦-恩曲他滨或阿巴卡韦-拉米夫定简化抗逆转录病毒治疗：一项随机、96 周试验。
Clin Infect Dis. 2009 Nov 15;49(10):1591-601. doi: 10.1086/644769.
6
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.在感染 HIV-1 的患者中，每日一次给予硫酸茚地那韦（2000 毫克）和利托那韦（100 毫克），并与阿巴卡韦/拉米夫定（600/300 毫克）或替诺福韦/恩曲他滨（245/200 毫克）的固定剂量组合联合使用。
J Antimicrob Chemother. 2009 Dec;64(6):1260-4. doi: 10.1093/jac/dkp348. Epub 2009 Sep 22.
7
[Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals].[两种新型核苷类似物固定制剂（替诺福韦-恩曲他滨和阿巴卡韦-拉米夫定）。针对初治患者和接受过抗逆转录病毒治疗的受试者，关于临床实践和治疗前景的前瞻性开放性研究]
Recenti Prog Med. 2008 Oct;99(10):492-501.
8
Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.恩曲他滨：新制剂。一种与拉米夫定非常相似的抗逆转录病毒药物。
Prescrire Int. 2005 Apr;14(76):54-6.
9
Emtricitabine/tenofovir (Truvada) for HIV prophylaxis.恩曲他滨/替诺福韦（特鲁瓦达）用于艾滋病病毒预防。
Am Fam Physician. 2013 Oct 15;88(8):535-40.
10
Zidovudine + lamivudine: new preparation. Fewer tablets required.齐多夫定+拉米夫定：新制剂。所需药片数量更少。
Prescrire Int. 1999 Apr;8(40):39-40.
Zotero 插件